Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin
Molecules · 2024
DOI: 10.3390/molecules29174095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Wjdan Jogadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Kent State University, 236 Integrated Sciences Building, Kent, OH 44242, USA. Hauptthemen laut MEDLINE: Cisplatin, Doxorubicin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Science Foundation, Kent State University.
Abstract (Originalsprache)
In this study, we report a novel platinum–doxorubicin conjugate that demonstrates superior therapeutic indices to cisplatin, doxorubicin, or their combination, which are commonly used in cancer treatment. This new molecular structure (1) was formed by conjugating an amphiphilic Pt(IV) prodrug of cisplatin with doxorubicin. Due to its amphiphilic nature, the Pt(IV)–doxorubicin conjugate effectively penetrates cell membranes, delivering both cisplatin and doxorubicin payloads intracellularly. The intracellular accumulation of these payloads was assessed using graphite furnace atomic absorption spectrometry and fluorescence imaging. Since the therapeutic effects of cisplatin and doxorubicin stem from their ability to target nuclear DNA, we hypothesized that the amphiphilic Pt(IV)–doxorubicin conjugate (1) would effectively induce nuclear DNA damage toward killing cancer cells. To test this hypothesis, we used flow the cytometric analysis of phosphorylated H2AX (γH2AX), a biomarker of nuclear DNA damage. The Pt(IV)–doxorubicin conjugate (1) markedly induced γH2AX in treated MDA-MB-231 breast cancer cells, showing higher levels than cells treated with either cisplatin or doxorubicin alone. Furthermore, MTT cell viability assays revealed that the enhanced DNA-damaging capability of complex 1 resulted in superior cytotoxicity and selectivity against human cancer cells compared to cisplatin, doxorubicin, or their combination. Overall, the development of this amphiphilic Pt(IV)–doxorubicin conjugate represents a new form of combination therapy with improved therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, Kent State University, 236 Integrated Sciences Building, Kent, OH 44242, USA.
- Department of Chemistry, University of Bisha, Bisha 67714, Saudi Arabia.
ORCID-Profile: Wjdan Jogadi, Man B Kshetri, Suha Alqarni, May Cheline
Förderung
- NIH HHS
- National Science Foundation
- Kent State University
- National Cancer Institute
- NSF Award
- Kent State University and LaunchPad Award and Small Research Grant
Zitieren
APA
Jogadi, W., Kshetri, M. B., Alqarni, S., Sharma, A., Cheline, M., Amin, M. A., Sheets, C., Nsoure-Engohang, A., & Zheng, Y. R. (2024). Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin. Molecules. https://doi.org/10.3390/molecules29174095
Vancouver
Jogadi W, Kshetri MB, Alqarni S, Sharma A, Cheline M, Amin MA, et al. Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin. Molecules. 2024. doi:10.3390/molecules29174095
BibTeX
@article{Jogadi2024,
author = {Jogadi, Wjdan and Kshetri, Man B and Alqarni, Suha and Sharma, Arpit and Cheline, May and Amin, Md Al and Sheets, Cynthia and Nsoure-Engohang, Angele and Zheng, Yao-Rong},
title = {Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29174095}
}
EUVIMED